June 23, 2017 6:23pm

 

It’s tough to knock the sector down as the IBB jumps +0.20%, The XBI +1.40% as the XLV dives -0.15% with the VIX -4.39% while the …

 

Russell index is rebalancing for the next year in a year marked by record-setting moves for U.S. equities

The impact of the Russell rebalance is likely to be felt in the final fleeting seconds, or fractions of seconds, as the market closes Friday, and as funds that track the Russell change their composition to reflect the rebalancing, which takes hold on Monday.

 

Pre-open indications re-cap: 6 hit and 2 miss

 

Out and about:  Stemline Therapeutics (STML +$0.60) presents SL-401 updated Stage 1 and 2 Data from ongoing pivotal trial in BPDCN and safety experience across multiple indications at EHA

 

I answer one question, in which company should investors commit and keep their money.

What have you missed, Friday’s results have implications to Monday's sector activity.  

 


 

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour post open was positive with an A/DL of 22/915 and 6 flats;

·         The mid-day was positive with an A/DL of 24/15 and 4 flat;

·         The close was positive with an A/DL of 24/14 and 5 flats;

 

 

Pre-open indications re-cap:  6 hit and 2 miss

  • Applied Genetic Technologies (AGTC) closed down -$0.10 – miss;
  • Athersys (ATHX) closed down -$0.03 – hit;
  • Biostage (BSTG) closed down -$0.041 – hit;
  • bluebird bio (BLUE) closed down -$6.50 – hit;
  • Juno Therapeutics (JUNO) closed up +$2.02 – hit;
  • Kite Pharma (KITE) closed up +$6.67 – hit;
  • Regenxbio (RGNX) closed up +$0.80 – miss;
  • Sangamo Therapeutics (SGMO) closed UP +$0.10 – hit;

 

 

Henry’omics:

From the pre-open’s investor’s newsletter … “Always a contrarian, as I feel the pain of past wounds when anxiety builds …”

  • Reiterating, “It’s ending the quarter next week topped-off by a holiday where many will exit … this market … untrusting what might come during it – so WHY be TOO LONG!”

Health care stocks pulled back about 0.1% on Friday, but the sector still notched a weekly gain of 3.7% to outperform the other spaces.

  • Overall, U.S. stocks closed slightly higher for the week, with the Dow and S&P posting small gains in the period.

When has a sprint lasted so long?

 

Watch your wallet, your portfolio is at risk  - next week!

 

 

Out and about:

Stemline Therapeutics, Inc. (STML) presented updated clinical data from Stages 1 and 2 of the ongoing SL-401 pivotal P2 clinical trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), along with safety data from the entire SL-401 clinical program, at the 22nd Congress of the European Hematology Association (EHA) being held in Madrid, Spain. A summary of the presentation is as follows:

 

·         Stages 1 and 2 enrolled 32 BPDCN patients, of which 19 were first-line and 13 patients were relapsed/refractory.

·         Median age was 72 years (range 29-85 years);

·         The most common treatment-related adverse events (TRAEs) with SL-401 across BPDCN and other indications (n=134 patients) were hypoalbuminemia (43%), transaminitis (43%), and thrombocytopenia (26%), by investigator-assessment. TRAEs included capillary leak syndrome (18%), of which 3 cases were grade 5 (2.2%), as previously reported;

·         The overall response rate (ORR) for Stage 1 and 2 BPDCN patients (n=32) was 84%, with a complete response (CR) rate of 59%, by investigator-assessment;

·         Eight BPDCN patients who achieved remission on SL-401 (for ~2.5 to ~6 months duration) were subsequently bridged to stem cell transplant, including one relapsed/refractory patient;

·         In first-line BPDCN patients treated at 12 ug/kg/day (n=16), the median overall survival (OS) has not been reached;

STML closed UP +$0.60 to $9.10 …

 

 

Daily analytics:

U.S. equities closed on Friday … with the DOW closing DOWN -0.01% (-2.53) as the NASDAQ closed UP +0.46% (+28.57) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, near 10.02 … down -4.39%

·Thursday’s traded near 10.5 … Wednesday traded near 10.75 – DOWN -1.01% following Tuesday’s  near 10.86% - UP +4.73% after Monday traded 10.24 down -1.35% and last Friday near 10.4

 

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a close of:

·         Friday traded +0.66%

·         Thursday +0.38%

·         Wednesday -0.25%

·         Tuesday -1.01%

·         Monday+0.74%

·         Last Friday -0.25%

… The iShares NASDAQ Biotechnology (IBB) indicated a close of:

·         Friday traded up +0.20%

·         Thursday +1.27%

·         Wednesday +4.12%

·         Tuesday +1.27%

·         Monday +2.41%

·         Last Friday -0.36%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners barely jump and %’s migrate……….

·         Friday’s decliners ranged from -0.31% <FATE> to -11.36% <BSTG> in  14  equities;

·         Thursday’s decliners ranged from -0.38% <MDXG> to -5.95% <ATHX> in  12  equities;

·         Wednesday’s decliners ranged from -0.13% <OSIR> to -4.23% <VTGN> in  13 equities;

·         Tuesday’s decliners ranged from -0.16% <BLCM> to -7.32% <BSTG> in  21 equities;

·         Monday’s decliners ranged from -0.47% <ADRO> to -8.33% <ISCO> in  7 equities;

·         Last Friday’s decliners ranged from -0.41% <NWBO> to -6.67% <CAPR> in  26 equities;

Versus

………… look at the percentage’s (%) and their decreases yet the upside remained close to the same…….

·         Friday’s gainers ranged from +0.28%  <XON> to +7.49% <JUNO> in 24 equities;

·         Thursday’s gainers ranged from +0.31%  <FATE> to +14.74% <NWBO> in 27 equities;

·         Wednesday’s gainers ranged from +0.38%  <ONVO> to +12% <ATHX> in 27 equities;

·         Tuesday’s gainers ranged from +0.31%  <BLUE> to +8.61% <NWBO> in 20 equities;

·         Monday’s gainers ranged from +0.20%  <QURE> to +13.92% <FCSC> in 35 equities;

·         Last Friday’s gainers ranged from +0.14%  <KITE> to +8.11% <BLCM> in 14 equities;

 

 

Some of MY working trend lines or indications for Tuesday:

… The greatest volume to the downside:  NWBO, BLUE, BLCM, BSTG and ATHX

… Upside volume was weighted to:  JUNO, BTX, KITE, SGMO and MDXG

… Biggest $ downside:  BLUE, ONCE, BLCM, AGTC and ADVM

… Largest $ upside: KITE, JUNO, CLLS, RGNX and STML                 

… Flat: RENE.L, PSTI, CYTX, AST and ISCO

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.